Crossmark

Cost-Effectiveness of Atezolizumab Plus Chemotherapy as First-Line Therapy for Metastatic Urothelial Cancer

Published Online: 2021-05-21

Published Print: 2021-06

Authors

Qin, Shuxia

Yi, Lidan

Li, Sini

Tan, Chongqing

Zeng, Xiaohui

Wang, Liting

Peng, Ye

Wan, Xiaomin https://orcid.org/0000-0001-5315-8141
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (71874209, 82073818)

Natural Science Foundation of Hunan Province (2019JJ40411)
License Information

Text and Data Mining valid from 2021-05-21

Version of Record valid from 2021-05-21
More Information

Article History

Received: 30 March 2021

Accepted: 7 May 2021

First Online: 21 May 2021

Document is current